Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society

@article{Harris2010ManagementOO,
  title={Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society},
  author={Steven T. Harris and David Kendler and Michael R. McClung and Stuart L. Silverman and JoAnn V. Pinkerton and Cynthia A. Stuenkel and Thomas Boston Clarkson and Elizabeth Contestabile and Shirley E. Greenberg and Victor W. Henderson and Risa Kagan and JoAnn E. Manson and Fay Brigham and Diane Todd Pace and Jan L. Shifren},
  journal={Menopause},
  year={2010},
  volume={17},
  pages={25-54}
}
Objective: To update the evidence-based position statement published by The North American Menopause Society (NAMS) in 2006 regarding the management of osteoporosis in postmenopausal women. Methods: NAMS followed the general principles established for evidence-based guidelines to create this updated document. A panel of clinicians and researchers expert in the field of metabolic bone diseases and/or women's health was enlisted to review the 2006 NAMS position statement, compile supporting… Expand

Paper Mentions

Interventional Clinical Trial
The purpose of this study is to identify the best way to prevent bone loss in the first years after menopause. The HOPS study will compare bone loss at 12 months in women: 1) who take… Expand
ConditionsOsteopenia
InterventionBehavioral, Drug
Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society
  • Medicine
  • Menopause
  • 2021
TLDR
Osteoporosis is a common disorder in postmenopausal women and lifelong management is necessary, and government-approved options include estrogen agonists/antagonists, bisphosphonates, RANK ligand inhibitors, parathyroid hormone-receptor agonists, and inhibitors of sclerostin. Expand
Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society
TLDR
Current evidence supports a consensus regarding the role of HT in postmenopausal women, when potential therapeutic benefits and risks around the time of menopause are considered. Expand
Denosumab for the Management of Postmenopausal Osteoporosis
TLDR
The introduction of denosumab into clinical practice provides physicians with another option for the treatment of postmenopausal osteoporosis, and the twice-yearly dosing regimen has the potential to improve adherence. Expand
POSTMENOPAUSAL OSTEOPOROSIS- AN UPDATED REVIEW
TLDR
The objective of the present review is to update all aspect of osteoporosis in postmenopausal women, including current etiology, diagnostic methods, calculator of osteOPorotic risk fators (FRAX), laboratory evaluation methods and biomarkers, drug therapy & newly approved drugs along with those under clinical trial. Expand
Foreword: an evidence-based update with regard to the diagnosis and management of osteoporosis.
  • P. Schnatz
  • Medicine
  • Clinical obstetrics and gynecology
  • 2013
TLDR
Osteoporosis has gained recognition as a significant health problem in the United States, especially with the advancing age of the baby boom population, and as it is often asymptomatic and unrecognized in the early stages, the condition is frequently under diagnosed and undertreated. Expand
Osteoporosis Knowledge, Beliefs, and Bone Promotion Behaviors of Postmenopausal African American (AA) Women
TLDR
Postmenopausal AA women’s knowledge, beliefs and behaviors concerning osteoporosis are described and exploration of correlations between the Health Belief Model (HBM) theoretical constructs with osteopOrosis preventive behavior, especially calcium intake and physical exercise is explored. Expand
Osteoporosis prevention, screening, and treatment: a review.
TLDR
Current recommendations in light of newer evidence are explored to provide more clarity on prevention, screening, and management strategies for patients with osteoporosis in the primary care setting. Expand
Osteoporosis screening and treatment guidelines: are they being followed?
TLDR
A large number of women are not properly screened or treated for osteoporosis, and inappropriate screening may also lead to improper management of bone density testing and its associated complications. Expand
Osteoporosis in Postmenopausal Women: Considerations in Prevention and Treatment (Women’s Health Series)
TLDR
Osteoporosis, the most common human bone disease, affects 8 million American women and has significant morbidity and mortality and preventive measures include avoiding smoking, excessive alcohol/caffeine intake, and falls in addition to maintaining adequate calcium/vitamin D intake and exercise. Expand
Screening for Osteoporosis to Prevent Fractures: Recommendation Statement.
  • Medicine
  • American family physician
  • 2018
TLDR
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for osteoporosis to prevent osteop orotic fractures in men. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 407 REFERENCES
Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society
  • Medicine
  • Menopause
  • 2006
TLDR
Management strategies for postmenopausal women involve identifying those at risk of low bone density and fracture, followed by instituting measures that focus on reducing modifiable risk factors through lifestyle changes and, if indicated, pharmacologic therapy. Expand
The role of calcium in peri- and postmenopausal women: 2006 position statement of the North American Menopause Society.
TLDR
There is strong support for the importance of ensuring adequate calcium intake in all women, particularly those in peri- or postmenopause, and clinicians should focus instead on encouraging women to consume enough calcium to meet the recommended levels. Expand
The role of calcium in peri-and postmenopausal women: consensus opinion of The North American Menopause Society
TLDR
Adequate calcium intake has been shown to prevent bone loss and reduce fracture risk in peri-and postmenopausal women, and a strong statement can be made regarding the importance of ensuring adequate calcium intake in all women, particularly those inperi-or postmenopause. Expand
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society
TLDR
Current evidence supports a consensus regarding the role of HT in postmenopausal women, when potential therapeutic benefits and risks around the time of menopause are considered, and a recommended list of areas for future HT research. Expand
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.
  • Jacques P Brown, R. Josse
  • Medicine
  • CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • 2002
TLDR
This document outlines detailed recommendations pertaining to all aspects of osteoporosis and recommends strategies for identifying those at increased risk and screening with central dual-energy x-ray absorptiometry at age 65 years are recommended. Expand
Rapid Loss of Hip Fracture Protection After Estrogen Cessation: Evidence From the National Osteoporosis Risk Assessment
TLDR
Postmenopausal women who have discontinued HT within the past 5 years have a risk for hip fracture that is at least as high as that in women who has never used HT. Expand
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.
  • S. Hodgson, N. Watts, +11 authors R. Recker
  • Medicine
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2003
TLDR
The AACE 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis address the prevention, diagnosis, and management of postmenopausal osteoporo-sis, a disorder that is recognized as a major public health problem because of its physical and socioeconomic consequences. Expand
Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society.
TLDR
The overall objective of these reports has been to make recommendations to both clinicians and the lay public about the appropriate role of HT for peri-and postmenopausal women. Expand
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group.
The criteria required for an effective screening strategy for osteoporosis are largely met in Caucasian women. The disease is common and readily diagnosed by the measurement of bone mineral withExpand
Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial
TLDR
A 3-year randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy of alendronate therapy in preventing bone loss in healthy women who had recently experienced menopause. Expand
...
1
2
3
4
5
...